NGOs Continue Fight To Remove Key Patent On Gilead’s Sovaldi
Executive Summary
NGOs are continuing their efforts to pave the way for lower-cost generic versions of Gilead’s breakthrough hepatitis C treatment Sovaldi and have appealed a decision by the European Patent Office to uphold a key patent relating to the drug.
You may also be interested in...
Sofosbuvir Patent Challenge Could Highlight Weaknesses In IP Systems
NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.